Tencent Unveils New AI Upgrades, Proprietary Innovations, and Global Solutions

New tools aim to empower enterprises to achieve new growth with digital-driven efficiency, capitalize on emerging trends and expand globally

Tencent Cloud reports strong international growth with consistent double-digit growth for three consecutive years

SHENZHEN, China, Sept. 5, 2024 /PRNewswire/ -- The Tencent Global Digital Ecosystem Summit, held at the Shenzhen World Exhibition & Convention Center from September 5-6, saw the unveiling of a slew of Cloud and Artificial Intelligence (AI) offerings, proprietary innovations, and global solutions for enterprises to advance their digital transformation efforts. 

Dowson Tong, Senior Executive Vice President of Tencent and CEO of the Cloud and Smart Industries Group (CSIG), highlighted the strong drive for new growth among enterprises. "Many enterprises are looking for breakthroughs in their business models. By harnessing digitalization to boost efficiency, capitalizing on emerging trends, and expanding their global footprint, they can unlock new levels of growth and innovation."

Tencent introduced several product suite upgrades to support the AI and digitalization goals of its partners and enterprises, including a full suite of computing, storage, and networking solutions known as "AI Infra", designed to optimize infrastructure as companies embrace large model development and training. Also unveiled was Tencent Hunyuan Turbo – a model service based on the Mixture of Experts (MoE) architecture. Tencent Hunyuan Turbo has doubled training efficiency and reduced inference costs by 50%. 

Today, Tencent Cloud's AI Coding Assistant, powered by the Hunyuan foundation model, is reportedly used by more than 50% of Tencent's programmers enhancing productivity by 40%. In addition, Tencent Meeting now offers features such as intelligent recording, an AI assistant, multilingual translation, and more, supporting over 15 million users each month.

State-of-the-art AI offerings for global enterprises    

In the international market, Tencent Cloud is scaling up its investments and resources to collaborate with clients and partners in its mission to 'Innovate, Connect, and Globalize'. 

In addition to introducing a new suite of AI and model training products and services in China, Tencent Cloud International unveiled a groundbreaking Palm Verification technology and an accompanying ecosystem plan in the overseas market to drive broader adoption of secure, AI-enabled identity authentication. 

Poshu Yeung, Senior Vice President of Tencent Cloud International noted that Tencent Cloud's Palm Verification solution has been globally piloted and is used by leading enterprises, including Indonesia's largest mobile internet provider, Telkomsel, to support diverse applications from payment systems to security access management.

Yeung added, "The Palm Verification Ecosystem Plan packages our technology into a versatile model kit, enabling global partners to quickly adopt and integrate this world-class technology for market deployment. This initiative empowers our partners to innovate and apply this technology across diverse business scenarios worldwide." 

Also at the event, several other AI-enabled products were unveiled for the overseas market, including the Knowledge Engine Platform, Digital Human, e-KYC and more, to empower enterprises in the AI era.

Global expansion gathers pace with key growth markets, strategic partnership

With the launch of these AI-powered offerings, Tencent Cloud's international business is set for continued growth, up and over the 10,000 businesses in 30 industries across 80+ markets and regions that it currently serves. 

Over the past three years, Tencent Cloud has achieved consistent double-digit growth in the international market, establishing a strong presence in Asia, Europe, the Americas, and the Middle East, with the Asia Pacific region seeing at least 50% year-on-year growth. 

Tong shared that the growth is fueled by demand for Tencent Cloud's unique ecosystem capabilities, world-class media technology services, and strong global infrastructure. "Enterprises in telecom, media, and public services leverage our flagship solutions, like the Mini Program platform, Real-Time Communication, Live-streaming, and Media solutions to transform operations and improve customer experience."

Tencent Cloud also has a proven track record in supporting businesses in their global expansion, having helped many Fortune 500 companies, including AstraZeneca, Mercedes-Benz, Toyota, and Walmart China, to successfully expand their presence in mainland China and globally. 

Also at the event, Tencent Cloud International announced major partnerships with several companies, namely Aladdin Cybersecurity, Avatara, MFEC Public Company, Siemens, S.M.A.R.T Entrepreneurship Club, UnionCloud, and others to explore new opportunities in AI, particularly in Digital Human solutions. These companies are now part of Tencent Cloud's Global Partner Ecosystem – a key driver of Tencent Cloud's international business – which has grown to 11,000 partners, contributing to 80% of revenue outside China.

In a bid to better serve the growing ecosystem of global partners and clients, Tencent Cloud has also established a global network of nine technical support centers across Indonesia, the Philippines, Malaysia, Singapore, Thailand, Japan, South Korea, the USA, and Germany, all of which will be providing round-the-clock technical service and support.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Tencent Unveils New AI Upgrades, Proprietary Innovations, and Global Solutions

SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).

This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.

According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×10⁹ PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.

By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.

"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."

About MVR-T3011

MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.

About ImmVira

ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS^® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients